LY-3410738

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLY-3410738
Drug Alias NameLY-3410738
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitors
TargetsIsocitrate dehydrogenase [NADP] cytoplasmic
Therapy Area/IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyLoxo Oncology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A